Seeking Alpha

Biotech Analysis Central Model 10+ Portfolio Old Pick#17 And Removed: Tempest Therapeutics; Phase 3 Study May Proceed TPST-1120, TPST-1495 Data 2025 And Catalysts

The next article I wanted to discuss for the Biotech Analysis Central Model 10+ Portfolio Old Pick #17 is a biotech by the name of Tempest Therapeutics (TPST). I want to state that I have chosen to ...
Seeking Alpha

Biotech Analysis Central Model 10+ Portfolio Old Pick#2 Arrowhead Pharmaceuticals; Plozasiran NDA Submission FCS, Sarepta Deal Up To $10 Billion Milestone Payments And Catalysts

The next article I wanted to discuss for the Biotech Analysis Central Model 10+ Portfolio Old Pick #2 is a biotech by the name of Arrowhead Pharmaceuticals (ARWR). The reason why I want to go over ...
Business Insider

Trinity Biotech Announces Collaboration to Advance Epigenetic Analysis for EpiCapture Prostate Cancer Test

DUBLIN, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including ...
Business Wire

Pharmaceuticals and Biotechnology Manufacturing and Supply Agreement Trends Analysis Report and Directory 2020-2025 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology 2020-2025" has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive ...
Nasdaq

Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes

New Taipei City, Taiwan, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to ...